Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age9-64
SponsorStanford University
About this trial
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 9 through 64 years
Diagnosed with COVID-19 at least 2 months prior enrollment
Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms
Patients without COVID-19 diagnosis for controls
Disqualifiers
Received the influenza vaccine less than 4 months ago
Pregnant or lactating
Patients with special risks attendant to venipuncture
Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment
Trial population
Adults (18-64 years) and children (9-17 years) diagnosed and not diagnosed (controls) with COVID-19 and who may have other medical conditions including long term COVID-19 symptoms, chronic fatigue, type 2 diabetes, and obesity.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Flu shot
Biological/VaccineAll participants will receive a single shot of the flu vaccine
Treatment groups
230 Participants
are divided into 2 treatment groupsGroup A: COVID-19 participants1 intervention
Group B: Control participants1 intervention
Trial outcomes
Primary outcomes
1
Testing immunity to the flu vaccine over time
Time frame
1 week2
Testing immunity to the flu vaccine over time
Time frame
1 monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Stanford University
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Source ClinicalTrials.gov